Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers

Masato Takahashi, Hidefumi Tonoki, Mitsuhiro Tada, Haruhiko Kashiwazaki, Keiji Furuuchi, Jun Ichi Hamada, Yasunori Fujioka, Yuji Sato, Hiromasa Takahashi, Satoru Todo, Noriaki Sakuragi, Tetsuya Moriuchi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A total of 76 primary breast cancers were screened for p53 mutations using the yeast p53 functional assay, and the mutations were determined by DNA sequencing. Clonal mutations of p53 were detected in 30 tumors (39%). Immunohistochemical staining for nuclear p53 accumulation performed on the yeast assay-positive cases clearly differentiated missense mutations in the DNA binding domain (contact mutant; 17 cases) as positive stain and nonsense- type mutations or missense mutations that may affect 3D-structure of p53 protein (structural mutant; 13 cases) as negative stain. Enzyme immunoassay revealed loss of estrogen receptor in 36 tumors (50%). Prognostic values of p53 mutation and loss of estrogen receptor were evaluated after a median follow-up period of 44 months, p53 mutations were associated with a short overall survival (log rank test, p = 0.0319), whereas it was not related to disease-free (recurrence-free) survival. Contact mutants were associated with slightly shorter survival compared with structural mutants. Inversely, loss of estrogen receptor was associated with early recurrence (p = 0.0461) but not with short overall survival. The patients with tumors harboring both p53 mutation and loss of estrogen receptor had the poorest outcome (p = 0.0019 and 0.0075 for overall and disease-free survivals, respectively), suggesting independent and additive effects of the 2 factors. The independent role of the 2 factors was confirmed by a multivariate analysis using the Cox proportional hazard model stratified according to clinical tumor stages. Although preliminary, due to the small number of patients studied and the relatively short follow-up time, our results suggest that p53 mutations and loss of estrogen receptor cooperatively affect the prognosis of primary breast cancer patients. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)92-99
Number of pages8
JournalInternational Journal of Cancer
Volume89
Issue number1
DOIs
Publication statusPublished - Jan 20 2000
Externally publishedYes

Fingerprint

Estrogen Receptors
Breast Neoplasms
Mutation
Survival
Missense Mutation
Neoplasms
Coloring Agents
Yeasts
Recurrence
Nonsense Codon
Mutant Proteins
Immunoenzyme Techniques
DNA Sequence Analysis
Proportional Hazards Models
Disease-Free Survival
Multivariate Analysis
Staining and Labeling
DNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. / Takahashi, Masato; Tonoki, Hidefumi; Tada, Mitsuhiro; Kashiwazaki, Haruhiko; Furuuchi, Keiji; Hamada, Jun Ichi; Fujioka, Yasunori; Sato, Yuji; Takahashi, Hiromasa; Todo, Satoru; Sakuragi, Noriaki; Moriuchi, Tetsuya.

In: International Journal of Cancer, Vol. 89, No. 1, 20.01.2000, p. 92-99.

Research output: Contribution to journalArticle

Takahashi, M, Tonoki, H, Tada, M, Kashiwazaki, H, Furuuchi, K, Hamada, JI, Fujioka, Y, Sato, Y, Takahashi, H, Todo, S, Sakuragi, N & Moriuchi, T 2000, 'Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers', International Journal of Cancer, vol. 89, no. 1, pp. 92-99. https://doi.org/10.1002/(SICI)1097-0215(20000120)89:1<92::AID-IJC15>3.0.CO;2-8
Takahashi, Masato ; Tonoki, Hidefumi ; Tada, Mitsuhiro ; Kashiwazaki, Haruhiko ; Furuuchi, Keiji ; Hamada, Jun Ichi ; Fujioka, Yasunori ; Sato, Yuji ; Takahashi, Hiromasa ; Todo, Satoru ; Sakuragi, Noriaki ; Moriuchi, Tetsuya. / Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. In: International Journal of Cancer. 2000 ; Vol. 89, No. 1. pp. 92-99.
@article{ebb96c3de9ab402b8bc7f263080537fb,
title = "Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers",
abstract = "A total of 76 primary breast cancers were screened for p53 mutations using the yeast p53 functional assay, and the mutations were determined by DNA sequencing. Clonal mutations of p53 were detected in 30 tumors (39{\%}). Immunohistochemical staining for nuclear p53 accumulation performed on the yeast assay-positive cases clearly differentiated missense mutations in the DNA binding domain (contact mutant; 17 cases) as positive stain and nonsense- type mutations or missense mutations that may affect 3D-structure of p53 protein (structural mutant; 13 cases) as negative stain. Enzyme immunoassay revealed loss of estrogen receptor in 36 tumors (50{\%}). Prognostic values of p53 mutation and loss of estrogen receptor were evaluated after a median follow-up period of 44 months, p53 mutations were associated with a short overall survival (log rank test, p = 0.0319), whereas it was not related to disease-free (recurrence-free) survival. Contact mutants were associated with slightly shorter survival compared with structural mutants. Inversely, loss of estrogen receptor was associated with early recurrence (p = 0.0461) but not with short overall survival. The patients with tumors harboring both p53 mutation and loss of estrogen receptor had the poorest outcome (p = 0.0019 and 0.0075 for overall and disease-free survivals, respectively), suggesting independent and additive effects of the 2 factors. The independent role of the 2 factors was confirmed by a multivariate analysis using the Cox proportional hazard model stratified according to clinical tumor stages. Although preliminary, due to the small number of patients studied and the relatively short follow-up time, our results suggest that p53 mutations and loss of estrogen receptor cooperatively affect the prognosis of primary breast cancer patients. (C) 2000 Wiley-Liss, Inc.",
author = "Masato Takahashi and Hidefumi Tonoki and Mitsuhiro Tada and Haruhiko Kashiwazaki and Keiji Furuuchi and Hamada, {Jun Ichi} and Yasunori Fujioka and Yuji Sato and Hiromasa Takahashi and Satoru Todo and Noriaki Sakuragi and Tetsuya Moriuchi",
year = "2000",
month = "1",
day = "20",
doi = "10.1002/(SICI)1097-0215(20000120)89:1<92::AID-IJC15>3.0.CO;2-8",
language = "English",
volume = "89",
pages = "92--99",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers

AU - Takahashi, Masato

AU - Tonoki, Hidefumi

AU - Tada, Mitsuhiro

AU - Kashiwazaki, Haruhiko

AU - Furuuchi, Keiji

AU - Hamada, Jun Ichi

AU - Fujioka, Yasunori

AU - Sato, Yuji

AU - Takahashi, Hiromasa

AU - Todo, Satoru

AU - Sakuragi, Noriaki

AU - Moriuchi, Tetsuya

PY - 2000/1/20

Y1 - 2000/1/20

N2 - A total of 76 primary breast cancers were screened for p53 mutations using the yeast p53 functional assay, and the mutations were determined by DNA sequencing. Clonal mutations of p53 were detected in 30 tumors (39%). Immunohistochemical staining for nuclear p53 accumulation performed on the yeast assay-positive cases clearly differentiated missense mutations in the DNA binding domain (contact mutant; 17 cases) as positive stain and nonsense- type mutations or missense mutations that may affect 3D-structure of p53 protein (structural mutant; 13 cases) as negative stain. Enzyme immunoassay revealed loss of estrogen receptor in 36 tumors (50%). Prognostic values of p53 mutation and loss of estrogen receptor were evaluated after a median follow-up period of 44 months, p53 mutations were associated with a short overall survival (log rank test, p = 0.0319), whereas it was not related to disease-free (recurrence-free) survival. Contact mutants were associated with slightly shorter survival compared with structural mutants. Inversely, loss of estrogen receptor was associated with early recurrence (p = 0.0461) but not with short overall survival. The patients with tumors harboring both p53 mutation and loss of estrogen receptor had the poorest outcome (p = 0.0019 and 0.0075 for overall and disease-free survivals, respectively), suggesting independent and additive effects of the 2 factors. The independent role of the 2 factors was confirmed by a multivariate analysis using the Cox proportional hazard model stratified according to clinical tumor stages. Although preliminary, due to the small number of patients studied and the relatively short follow-up time, our results suggest that p53 mutations and loss of estrogen receptor cooperatively affect the prognosis of primary breast cancer patients. (C) 2000 Wiley-Liss, Inc.

AB - A total of 76 primary breast cancers were screened for p53 mutations using the yeast p53 functional assay, and the mutations were determined by DNA sequencing. Clonal mutations of p53 were detected in 30 tumors (39%). Immunohistochemical staining for nuclear p53 accumulation performed on the yeast assay-positive cases clearly differentiated missense mutations in the DNA binding domain (contact mutant; 17 cases) as positive stain and nonsense- type mutations or missense mutations that may affect 3D-structure of p53 protein (structural mutant; 13 cases) as negative stain. Enzyme immunoassay revealed loss of estrogen receptor in 36 tumors (50%). Prognostic values of p53 mutation and loss of estrogen receptor were evaluated after a median follow-up period of 44 months, p53 mutations were associated with a short overall survival (log rank test, p = 0.0319), whereas it was not related to disease-free (recurrence-free) survival. Contact mutants were associated with slightly shorter survival compared with structural mutants. Inversely, loss of estrogen receptor was associated with early recurrence (p = 0.0461) but not with short overall survival. The patients with tumors harboring both p53 mutation and loss of estrogen receptor had the poorest outcome (p = 0.0019 and 0.0075 for overall and disease-free survivals, respectively), suggesting independent and additive effects of the 2 factors. The independent role of the 2 factors was confirmed by a multivariate analysis using the Cox proportional hazard model stratified according to clinical tumor stages. Although preliminary, due to the small number of patients studied and the relatively short follow-up time, our results suggest that p53 mutations and loss of estrogen receptor cooperatively affect the prognosis of primary breast cancer patients. (C) 2000 Wiley-Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034688187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034688187&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(20000120)89:1<92::AID-IJC15>3.0.CO;2-8

DO - 10.1002/(SICI)1097-0215(20000120)89:1<92::AID-IJC15>3.0.CO;2-8

M3 - Article

C2 - 10719737

AN - SCOPUS:0034688187

VL - 89

SP - 92

EP - 99

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -